drugset / Trial / NCT01453855

Travoprost 3-Month Safety and Efficacy Study

NCT01453855

Phase 3 Completed 1099 enrolled Alcon Research
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study was to demonstrate that the intraocular pressure-lowering efficacy of Travoprost 0.003% is equivalent to TRAVATAN® in adult patients with open-angle glaucoma or ocular hypertension.

Timeline

Start
2011-11
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Travoprost Other / unclassified 0.003 % Other
Subject Travoprost Other / unclassified 0.004 % Other